Literature DB >> 14990736

The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.

Michael B Zwick1, H Kiyomi Komori, Robyn L Stanfield, Sarah Church, Meng Wang, Paul W H I Parren, Renate Kunert, Hermann Katinger, Ian A Wilson, Dennis R Burton.   

Abstract

The human monoclonal antibody 2F5 neutralizes primary human immunodeficiency virus type 1 (HIV-1) with rare breadth and potency. A crystal structure of a complex of 2F5 and a peptide corresponding to its core epitope on gp41, ELDKWAS, revealed that the peptide interacts with residues at the base of the unusually long (22-residue) third complementarity-determining region of the heavy chain (CDR H3) but not the apex. Here, we perform alanine-scanning mutagenesis across CDR H3 and make additional substitutions of selected residues to map the paratope of Fab 2F5. Substitution of residues from the base of the H3 loop or from CDRs H1, H2, and L3, which are proximal to the peptide, significantly diminished the affinity of Fab 2F5 for gp41 and a short peptide containing the 2F5 core motif. However, nonconservative substitutions to a phenylalanine residue at the apex of the H3 loop also markedly decreased 2F5 binding to both gp41 and the peptide, suggesting that recognition of the core epitope is crucially dependent on features at the apex of the H3 loop. Furthermore, substitution at the apex of the H3 loop had an even more pronounced effect on the neutralizing activity of 2F5 against three sensitive HIV-1. These observations present a challenge to vaccine strategies based on peptide mimics of the linear epitope.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990736      PMCID: PMC353725          DOI: 10.1128/jvi.78.6.3155-3161.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  gp120: Biologic aspects of structural features.

Authors:  P Poignard; E O Saphire; P W Parren; D R Burton
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

2.  Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein.

Authors:  E Coëffier; J M Clément; V Cussac; N Khodaei-Boorane; M Jehanno; M Rojas; A Dridi; M Latour; R El Habib; F Barré-Sinoussi; M Hofnung; C Leclerc
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

3.  Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Authors:  C E Parker; L J Deterding; C Hager-Braun; J M Binley; N Schülke; H Katinger; J P Moore; K B Tomer
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

5.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.

Authors:  J R Mascola; G Stiegler; T C VanCott; H Katinger; C B Carpenter; C E Hanson; H Beary; D Hayes; S S Frankel; D L Birx; M G Lewis
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

6.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.

Authors:  T W Baba; V Liska; R Hofmann-Lehmann; J Vlasak; W Xu; S Ayehunie; L A Cavacini; M R Posner; H Katinger; G Stiegler; B J Bernacky; T A Rizvi; R Schmidt; L R Hill; M E Keeling; Y Lu; J E Wright; T C Chou; R M Ruprecht
Journal:  Nat Med       Date:  2000-02       Impact factor: 53.440

7.  Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.

Authors:  M B Zwick; L L Bonnycastle; A Menendez; M B Irving; C F Barbas; P W Parren; D R Burton; J K Scott
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

8.  Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA.

Authors:  S G Sarafianos; K Das; C Tantillo; A D Clark; J Ding; J M Whitcomb; P L Boyer; S H Hughes; E Arnold
Journal:  EMBO J       Date:  2001-03-15       Impact factor: 11.598

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 10.  The antiviral activity of antibodies in vitro and in vivo.

Authors:  P W Parren; D R Burton
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

View more
  63 in total

1.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Scaffolding to build a rational vaccine design strategy.

Authors:  Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

3.  Elicitation of structure-specific antibodies by epitope scaffolds.

Authors:  Gilad Ofek; F Javier Guenaga; William R Schief; Jeff Skinner; David Baker; Richard Wyatt; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

4.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.

Authors:  Mikyung Kim; Zhen-Yu J Sun; Kasper D Rand; Xiaomeng Shi; Likai Song; Yuxing Cheng; Amr F Fahmy; Shreoshi Majumdar; Gilad Ofek; Yongping Yang; Peter D Kwong; Jia-Huai Wang; John R Engen; Gerhard Wagner; Ellis L Reinherz
Journal:  Nat Struct Mol Biol       Date:  2011-10-16       Impact factor: 15.369

5.  Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.

Authors:  Wu Ou; Jonathan Silver
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

Review 6.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

7.  Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis.

Authors:  Ralph Pantophlet; Rowena O Aguilar-Sino; Terri Wrin; Lisa A Cavacini; Dennis R Burton
Journal:  Virology       Date:  2007-04-06       Impact factor: 3.616

8.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.

Authors:  Erin M Scherer; Daniel P Leaman; Michael B Zwick; Andrew J McMichael; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

10.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.